Sophion Bioscience Revenue and Competitors

Ballerup, Den

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Sophion Bioscience's estimated annual revenue is currently $18.3M per year.(i)
  • Sophion Bioscience's estimated revenue per employee is $155,000

Employee Data

  • Sophion Bioscience has 118 Employees.(i)
  • Sophion Bioscience grew their employee count by 8% last year.

Sophion Bioscience's People

NameTitleEmail/Phone
1
Marketing Communications and Event ManagerReveal Email/Phone
2
Operations ManagerReveal Email/Phone
3
Application ScientistReveal Email/Phone
4
SW DeveloperReveal Email/Phone
5
Application ScientistReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$28.5M18437%N/AN/A
#2
$20.6M1334%N/AN/A
#3
$25.3M16327%N/AN/A
#4
$9.3M60-27%N/AN/A
#5
$88.8M57327%N/AN/A
#6
$12.7M82-2%N/AN/A
#7
$6.8M44-28%N/AN/A
#8
$7.4M48-19%N/AN/A
#9
$88.8M57327%N/AN/A
#10
$18.3M1188%N/AN/A
Add Company

What Is Sophion Bioscience?

Sophion was founded in the year 2000 by a group of passionate electrophysiologists, all having the shared purpose of making patch clamping objective and independent of user skills to provide faster, more accurate and objective patch clamping results. “To take the voodoo out of patch clamping”. Over the past twenty years, we have developed from a startup into a global organization, but the passion and drive to provide high-performance patch clamp solutions persist. With our complete technical, biological and application support we help our partners to achieve their targets, and through the continued development of our QPatch and Qube platforms, we ensure that we offer uncompromised data quality in a user-friendly environment from assay setup to data analysis.

keywords:N/A

N/A

Total Funding

118

Number of Employees

$18.3M

Revenue (est)

8%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$33.9M14024%N/A
#2
$41.8M15526%N/A
#3
$20.6M187-7%N/A
#4
$40.4M2535%N/A
#5
$93.2M3129%N/A